2. Signaling Pathways
  3. GPCR/G Protein
  4. LPL Receptor
  5. LPAR2 Isoform

LPAR2

 

LPAR2 Related Products (6):

Cat. No. Product Name Effect Purity
  • HY-107616
    H2L5186303
    		Antagonist 98.50%
    H2L5186303 is a potent and selective LPA2 receptor antagonist with an IC50 of 9 nM. H2L5186303 promotes Apoptosis. H2L5186303 inhibits cell proliferation and motility. H2L5186303 has anti-inflammatory effects.
  • HY-100676
    GRI977143
    		Agonist 99.29%
    GRI977143 is a specific LPA2 receptor agonist, with an EC50 of 3.3 μM .
  • HY-178845
    Decyl phosphate
    		Modulator
    Decyl phosphate is a selective LPA2 agonist (EC50: 1.8 μM) and LPA1/LPA3 antagonist. Decyl phosphate can be used in the research of blood disorders.
  • HY-118539
    NSC12404
    		Agonist
    NSC12404 is a weak and specific LPA2 receptor agonist.
  • HY-148291
    BrP-LPA sodium
    		Antagonist
    BrP-LPA sodium is a pan-opposite agent for lysophosphatidic acid (LPA). It has antagonistic activity against LPA1 (IC50 = 4520 nM), LPA2 (IC50 = 468 nM), LPA3, and LPA4. BrP-LPA sodium also has partial agonistic activity for LPA5, with its EC50 being 1282 nM. BrP-LPA sodium has ATX inhibitory activity. BrP-LPA sodium effectively inhibits the migration and invasion of breast cancer cells. BrP-LPA sodium achieves tumor regression and anti-angiogenesis in mice breast cancer xenograft model. BrP-LPA sodium can be used for the study of breast cancer.
  • HY-W725737
    BrP-LPA
    		Antagonist
    BrP-LPA is a LPA antagonist/ATX inhibitor. BrP-LPA shows pan-antagonist activity towards LPA1-4 GPCRs. BrP-LPA decreases blood vessel density. BrP-LPA dose-dependently inhibits Lysophosphatidic acid-induced head-dip counts. BrP-LPA exhibits anticancer activity against breast cancer, colon cancer, and lung cancer. BrP-LPA inhibits anxiety-like behavior.